Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company, announced that Mel Sorensen, M.D., CEO, will engage in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded event will be available from November 23, 2020, on Galera's Investor page for 60 days. Galera focuses on innovative therapeutics for cancer radiotherapy, including lead candidate avasopasem manganese (GC4419), targeting radiation-induced severe oral mucositis.
- None.
- None.
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
The pre-recorded fireside chat can be accessed beginning November 23, 2020, from the Investors page of Galera’s website, investors.galeratx.com, and will remain available for 60 days following the conference.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera’s second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 clinical trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
Jennifer Porcelli
Solebury Trout
646-378-2962
jporcelli@soleburytrout.com
Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
FAQ
What is Galera Therapeutics discussing at the Piper Sandler Healthcare Conference?
When can I access the pre-recorded fireside chat by Galera Therapeutics?
What is the lead product candidate of Galera Therapeutics?
What is the significance of avasopasem in relation to cancer treatment?
What clinical trials is Galera Therapeutics conducting with avasopasem?
